← Leaderboards
Golam Mohi
University Of Virginia
$10,072,497
Attributed
$10,072,497
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,072,497 · 10
By mechanism
R01$7,735,248 · 4
R21$2,337,249 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia
Same institution · by research overlap
- Jeffrey Chunlong Xing$185,468
Others in their field
Top investigators on “Hematopoietic”
- Mary M Horowitz · Medical College Of Wisconsin$225,743,807
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$75,636,774
- Effie W Petersdorf · Fred Hutchinson Cancer Research Center$46,290,940
- Megan Sykes · Columbia University Health Sciences$41,013,082
- David T Scadden · Massachusetts General Hospital$37,607,985
- Bruce R. Blazar · University Of Minnesota$36,961,789
Research focus
HematopoieticCellsKnock-In MouseMutationMyelogenousMolecularPathogenesisMyeloproliferative DiseaseCell LineageNew Therapeutic TargetSignal TransductionHematologic NeoplasmsHemorrhagic ThrombocythemiaProtein Tyrosine KinasePolycythemia VeraNovel Therapeutic InterventionJak2 GenePlayKnock-DownMediatingAnimal ModelCell LineInsightHematopoietic Stem Cells
Grant awards (32)
Molecular Basis for Progression of Myeloproliferative Neoplasms Induced by JAK2V617F$601,169
R01 · FY2025 · HL · contact PI
Molecular Basis for Myelodysplasia Induced by U2AF1 Mutations$581,381
R01 · FY2025 · HL · contact PI
Molecular Basis for Myelodysplasia Induced by U2AF1 Mutations$569,754
R01 · FY2024 · HL · contact PI
Targeting of IL-1 Signaling in Myelofibrosis$215,179
R21 · FY2024 · CA · contact PI
Molecular Basis for Myelodysplasia Induced by U2AF1 Mutations$581,381
R01 · FY2023 · HL · contact PI
The Role of PTPN11 in Myelofibrosis$399,195
R01 · FY2023 · HL · contact PI
Targeting of IL-1 Signaling in Myelofibrosis$188,753
R21 · FY2023 · CA · contact PI
The Role of PTPN11 in Myelofibrosis$399,195
R01 · FY2022 · HL · contact PI
The Role of PTPN11 in Myelofibrosis$399,195
R01 · FY2021 · HL · contact PI
The Role of PTPN11 in Myelofibrosis$399,195
R01 · FY2020 · HL · contact PI
Targeting of CDK6 in Myelofibrosis$210,758
R21 · FY2020 · CA · contact PI
Efficacy of Allosteric SHP2 Inhibitor in RAS Mutant-Driven Myeloid Neoplasms$175,631
R21 · FY2020 · CA · contact PI
Targeting of CDK6 in Myelofibrosis$175,631
R21 · FY2019 · CA · contact PI
Efficacy of Allosteric SHP2 Inhibitor in RAS Mutant-Driven Myeloid Neoplasms$140,505
R21 · FY2019 · CA · contact PI
Role of JAK2V617F in the Pathogenesis of Myeloproliferative Neoplasms$403,750
R01 · FY2018 · HL · contact PI
Role of JAK2V617F in the Pathogenesis of Myeloproliferative Neoplasms$402,500
R01 · FY2017 · HL · contact PI
Targeting of Tyrosine Phosphatase SHP2 in Myeloproliferative Neoplasms$181,974
R21 · FY2017 · CA · contact PI
Role of PTPN1 in myeloid malignancies$175,133
R21 · FY2017 · CA · contact PI
Role of JAK2V617F in the Pathogenesis of Myeloproliferative Neoplasms$2,500
R01 · FY2017 · HL · contact PI
Role of JAK2V617F in the Pathogenesis of Myeloproliferative Neoplasms$405,000
R01 · FY2016 · HL · contact PI
Targeting of Tyrosine Phosphatase SHP2 in Myeloproliferative Neoplasms$224,929
R21 · FY2016 · CA · contact PI
Role of PTPN1 in myeloid malignancies$1,042
R21 · FY2016 · CA · contact PI
Role of JAK2V617F in the Pathogenesis of Myeloproliferative Neoplasms$402,500
R01 · FY2015 · HL · contact PI
Role of PTPN1 in myeloid malignancies$210,214
R21 · FY2015 · CA · contact PI
Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.$369,923
R01 · FY2013 · HL · contact PI
Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.$388,575
R01 · FY2012 · HL · contact PI
Inhibition of Histone Deacetylase in Myeloproliferative Neoplasms$199,375
R21 · FY2012 · HL · contact PI
Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.$392,500
R01 · FY2011 · HL · contact PI
Efficacy of Histone Deacetylase Inhibitor Vorinostat in Myeloproliferative Neopla$238,125
R21 · FY2011 · HL · contact PI
Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.$392,500
R01 · FY2010 · HL · contact PI
Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.$392,500
R01 · FY2009 · HL · contact PI
Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.$252,535
R01 · FY2009 · HL · contact PI